Pagani O, Regan MM, Fleming GF, et al. Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials. SABCS 2017, GS4-02.
Associatie tussen obesitas en kanker: een 'umbrella' review?
mrt 2017 | Borstkanker, Gynaecologische oncologie, Maag-darm-leveroncologie